Loxapine inhalation powder (adasuve): A new and innovative formulation of an antipsychotic treatment for agitation

P and T

Volumn 39, Issue 9, 2014, Pages

  Valdes, Jose ^a   Shipley, Travis ^a   Rey, Jose A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; LOXAPINE; NEUROLEPTIC AGENT; OPIATE; PLACEBO; SEDATIVE AGENT;

ADULT; AGED; AGITATION; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DSM-IV; DYSGEUSIA; DYSPNEA; DYSTONIA; FATIGUE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; NAUSEA; NOTE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH DISCOMFORT; THORAX PAIN; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; WHEEZING;

EID: 84911471922     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (15)

1. Murray CJL, Lopez AD. The Global Burden of Disease. Cambridge, Massachusetts: Harvard University Press; 1996.
2. National Institute of Mental Health. Schizophrenia. Available at: http://www.nimh.nih.gov/health/publications/schizophrenia/schizophrenia-booket-2009.pdf. Accessed October 3, 2013.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, Virginia: American Psychiatric Publishing; 2013.
4. Ballester J, Goldstein T, Goldstein B, et al. Is bipolar disorder specifically associated with aggression? Bipolar Disord 2012;14(3):283-290.
5. Binder RL, McNiel DE. Effects of diagnosis and context on dangerousness. Am J Psychiatry 1988;145(6):728-732.
6. Barlow K, Grenyer B, Ilkiw-Lavalle O. Prevalence and precipitants of aggression in psychiatric inpatient units. Aust N Z J Psychiatry 2000;34(6):967-974.
7. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007;64(5): 543-552.
8. Allen MH, Currier GW, Hughes DH, et al. The expert consensus guideline series. Treatment of behavioral emergencies. J Psychiatr Pract 2005;11(suppl 1):5-108.
9. Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 2012;14(1):31-40.
10. Budavari S., ed. The Merck Index-An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, New Jersey: Merck and Co., Inc., 1996:955.
11. Adasuve (loxapine inhalation powder) package insert. Mountain View, California: Alexza Pharmaceuticals, Inc.; December 2012.
12. Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed August 5, 2014.
13. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry 2011;72(10):1313-1321.
14. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebocontrolled study of inhaled loxapine. Br J Psychiatry 2011;198(1):51-58.
15. Food and Drug Administration. Clinical mreview of Adasuve. November 8, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM282897.pdf. n continued from page 623